Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
Patients will be enrolled in two stages:
- Dose-escalation stage: Approximately 15-30 patients will be enrolled.
- Dose-expansion stage: 6-12 patients will be enrolled. Dose-escalation slots will be
filled first, then dose-expansion slots.